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ABSTRACTSCharacteristic curve analysis was used to establish accuracy, sensitivity and
speciﬁcity compared to pathological stage.
Results: Of 425 patients, 83 met the inclusion criteria. Accuracy for T4
disease was 88.2% ERUS and 83.8% MRI. MRI had greater sensitivity than
ERUS for nodal stage (69.2% vs 48%) but lower speciﬁcity (52.4% vs 69%).
Post-chemotherapy MRI had greater accuracy (93.8%) and speciﬁcity
(100%) for ypT0 disease than ERUS (84.6% and 91.7%). ERUS was more
sensitive for nodal sterilisation (ypN0) than MRI (75% vs 37.8%), although
accuracy was poor in both modalities (53.8% and 48.8%).
Conclusion: ERUS is a valuable adjunct to MRI in local staging of rectal
cancer and may be superior in detecting T4 disease and nodal response
post-radiotherapy. Restaging of rectal cancer following chemoradiation
continues to be a challenging problem.
1332: COLONOSCOPY UNDER ENTONOX IS FEASIBLE AND IS ASSOCI-
ATED WITH POTENTIAL COST SAVINGS: A REVIEW OF A DGH
EXPERIENCE
Mostafa Abdel-Halim, Suzanne Langley, Manish Kaushal. Furness General
Hospital, Barrow-in-Furness, UK.
Aim: Entonox has been proposed as an alternative to intravenous sedation
during colonoscopy, but is rarely used. This study aims to establish the
efﬁcacy and cost-effectiveness of Entonox as the sole analgesic during
colonoscopy.
Methods: A prospectively-held database was reviewed. Practice involved
offering Entonox as the sole analgesic, with provision of IV sedation and
analgesia to patients who refuse or cannot complete the procedure under
Entonox. Potential cost savings was calculated.
Results: The total of 322 procedures performed during 18 months' period
was studied. Fifty percent attempted Entonox, whilst the rest requested IV
sedation. The majority who attempted Entonox (146, 91%) completed the
procedure without additional analgesia, whilst 15 (9%) required so.
Average comfort score was similar in the Entonox and Sedation groups.
Rate of successful caecal intubation and proportion of patients diagnosed
with polypswere similar between groups. Cost savings achievable by using
Entonox were calculated as £1.65/patient. In our department, this poten-
tially amounts to £789-£1754 annually depending on the rate of Entonox
uptake by patients.
Conclusions: Entonox is an effective analgesic during colonoscopy in
signiﬁcant proportion of patients. This practice has potential cost savings,
and can be associated with quicker recovery without compromising
diagnostic yield or comfort scores.
1346: DIVERTING ILEOSTOMY SITE CLOSURE HERNIATION: HOW MUCH
OF A PROBLEM IS IT?
Zubair Saeed, Shruti Patel, Rami Radwan, Brian Stephenson. Royal Gwent
Hospital, Newport, UK.
Aims: The prevalence of abdominal wall herniation at the site of a reversed
ileostomy is uncertain. This study investigated the prevalence of CT ab-
normalities at the site of a reversed loop ileostomy.
Methods: Data over a 5 year period was used. Cancer surveillance CT
images were graded as to deﬁned anatomical abnormalities (0-normal; I-
atrophy; II-defect(s) & III-herniation).
Results: 59 patients (mean age 65 years; range: 29-79) had ileostomies
closed (median time 6 months; range: 2-22). 43 underwent surveillance
CTs at 1-3 years. One year after reversal, abnormalities (atrophy or defects)
in the anterior abdominal wall were apparent in 37%. At 2 years, CTs in 4
patients (14%) were ‘re-graded'; two developed some degree of atrophy
(grade 0 to I), in one a defect appeared (grade I to II) and in one an
asymptomatic herniawas found (grade I to III). None of the 12 patients with
serial CTs at 3 years developed changes as compared to their 2 year scan.
Conclusion: Defects in the anterior abdominal wall at the site of a closed
ileostomy are not uncommon. Their frequency increases with length of
follow-up but true herniation is unusual. The routine use of prophylactic
mesh at ileostomy closure is unnecessary.
1381: EXPLORING THE USE OF ROUTINE BLOOD TESTS TO PREDICT
PATHOLOGICAL RESPONSE TO TREATMENT IN PATIENTS RECEIVING
NEOADJUVANT THERAPY FOR RECTAL CANCER
Stephan Dreyer, Arfon Powell, Paul Horgan, James Going, Joanne Edwards.
Univerity of Glasgow, Glasgow, UK.Aims: The aim of this study is to examine the relationship between pre-
neoadjuvant CRP, Albumin, Haemoglobin (Hb), neutrophil-lymphocyte
ration (NLR), platelet-lymphocyte ration (PLR) and tumour regression in
patients receiving neoadjuvant therapy for rectal cancer.
Methods: Patients undergoing neoadjuvant therapy for rectal cancer were
studied. Radiology reports, routine blood results including CRP, Albumin,
NLR, Hb, NLR, PLR were recorded. Routine Haematoxylin and Eosin stained
slides were reviewed to determine the tumour regression grade (TRG).
Results: 118 patients were studied; 40% had a TRG associated with a good
response, 45% had no radiological response, 42% showed downstaging and
13% showed stage progression. On Chi-squared analysis, radiological
response (P¼0.008), older age (P¼0.010) and an elevated CRP (P¼0.017)
was associated with poor pathological response. Only an elevated
PLR(P¼0.016) was associated with poor radiological response. On DFS
analysis, radiological response (P¼0.007), TRG (P¼0.042), raised CRP
(P¼0.001)andLow Hb (P¼0.007) were associated with poorer survival. On
multivariate survival analysis only raised CRP (Hazard Ratio 2.45 95%
Conﬁdence Interval (1.16-5.16);P¼0.019) was independently associated
with poorer survival.
Conclusion: This study demonstrates an association between routine
blood parameters and response to therapy. Delineating this association my
further support the use of these parameters in decision making on neo-
adjuvant therapy.1387: A SINGLE INSTITUTION EXPERIENCE OF ILEAL-POUCH ANAL
ANASTOMOSIS
Naomi M. Fearon, Cliodhna Browne, Maria C. Whelan, Paul C. Neary.
Tallaght Hospital, Dublin, Ireland.
Aims: The purpose of this study was to assess the outcomes in patients
who have undergone laparoscopic Ileal-Pouch Anal Anastomosis (J Pouch).
Methods: A retrospective review was carried out of patients who had J
pouch surgery between 2008-2013. Complications were grouped into time
periods and graded according to the Clavien Dindo Classiﬁcation. Func-
tional outcomes were assessed using The Gastrointestinal Quality of Life
Index and Wexner Scoring Systems.
Results: Forty two patients were identiﬁed. 20 of these underwent lapa-
roscopic surgery. The majority were male (90%) and had a diagnosis of
ulcerative colitis (95%). The median LOS for completion surgery was 6 days
(3-11 days). There were no immediate complications, 20% of patients had
an early complication, 15% had a late complication. There were no Grade IV
or V complications, 10% were classed as Grade III, the rest were Grade I and
II. Half of patients gave aWexner score 0 indicating no faecal incontinence,
11% gave a score above 5/20. The median frequency of daily bowel
movements was 5.5(1 e 12) and nocturnal was 1.5.
Conclusions: Patients who undergo laparoscopic J pouch surgery
generally have good results. The complication rate compares favourably
to international standards and functional outcomes are promising.1401: PATIENTS REFERRED WITH ANAEMIA INVESTIGATED BY ENDOS-
COPY: DOES ANAEMIA SUBTYPE MATTERS?
Daniel Thomas, Firas Hussain, Rajab Kerwat. Queen May Hospital, Sidcup,
Kent, UK.
Aim: To assess if non-microcytic or non-iron deﬁciency anaemia has a
similar cancer risk as microcytic anaemia.
Method: Eighteen-month retrospective study of all patients who had
endoscopies where anaemia was mentioned as an indication within an
endoscopy database at a District general hospital.
Results: 358 cases were identiﬁed, 203 females and 155 males. Age
ranged from 18 to 93 years with a mean, median and mode of 67, 69 and
82 respectively. Anaemia subtypes were known for 306 patients
(macrocytic-19, microcytic-138, normocytic -149). 3 patients had upper
gastrointestinal cancer and 25 patients had colorectal cancer including
synchronous colorectal cancers in 2 patients (1 microcytic, 1normo-
cytic). Overall cancer risk in this study is 7.82%. Upper gastrointestinal
cancer risks in patients according to anaemia subtype were macrocytic
(0%), microcytic (0.7%) and normocytic (1.3%). Colorectal cancer risks in
patients according to anaemia subtype were macrocytic (5.2%), micro-
cytic (8.7%) and normocytic (6.7%).
Conclusions: Non-microcytic anaemia appears to pose a clinically
important risk of cancer. Comparing microcytic to normocytic anaemia;
